<div id="readability-page-1"><p>Wedbush analyst David Nierengarten maintained a Buy rating on Beam Therapeutics today and set a price target of $57.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, AnaptysBio, and Oric Pharmaceuticals. According to TipRanks, Nierengarten has an average return of <span>19.5%</span> and a 50.10% success rate on recommended stocks. </p> <p>In addition to Wedbush, Beam Therapeutics also received a Buy from Bank of America Securities’s Alec Stranahan in a report issued today. However, on November 26, TR | OpenAI – 4o reiterated a Hold rating on Beam Therapeutics (NASDAQ: BEAM).</p></div>

BEAM

<p>Wedbush analyst David Nierengarten maintained a Buy rating on Beam Therapeutics with a $57 price target. Bank of America Securities also issued a Buy rating, while TR | OpenAI reiterated a Hold rating. Nierengarten, focusing on healthcare stocks, has an average return of 19.5% and a 50.10% success rate. The news highlights investment research opinions on Beam Therapeutics.</p>

Beam Therapeutics (BEAM) Receives a Buy from Wedbush